#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Celator appoints Jean-Pierre Bizzari to board

Share on Twitter Share on LinkedIn
Staff writer | Ewing, N.J., USA | March 3, 2015
CelatorMarch 3, 2015, Ewing, N.J., USA - Celator Pharmaceuticals, Inc., a biopharmaceutical company, announced the appointment of Jean-Pierre Bizzari to its board of directors.
Dr. Bizzari has served as Executive Vice-President, Group Head, Clinical Oncology Development at Celgene Corporation since joining the company in 2008. Dr. Bizzari was responsible for Celgene's clinical development, operations and statistics organization, which spans the U.S., Europe and Asia/Japan.

In addition, Dr. Bizzari was Chairman of Celgene's hematology oncology development committee and a member of the company's management committee.

Prior to joining Celgene, Dr. Bizzari was Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin (oxaliplatin), Taxotere (docetaxel) and Elitek (rasburicase).

Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhone-Poulenc Rorer (Aventis).

Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute and is a board member of Transgene and Halozyme Therapeutics.

He received his medical degree from the University of Nice (France) and is an oncologist, having trained at La Pitie-Salpetriere hospital in Paris, followed by training at the Ontario Cancer Institute and McGill Cancer Center.


 LATEST MOVES FROM New Jersey 


MORE INSIDE POST